Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/hepr.13828 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effectiveness of glecaprevir/pibrentasvir in HIV/HCV-coinfected patients treated with bictegravir/emtricitabine/tenofovir alafenamide.
Clin Exp Hepatol
September 2024
Department of Infectious Diseases and Hepatology, Medical University of Białystok, Białystok, Poland.
Aim Of The Study: To assess the real-life efficacy and safety of glecaprevir/pibrentasvir (GLE/PIB) in HIV/HCV- positive patients treated with bictegravir/emtricitabine/tenofovir alafenamide (B/FTC/TAF).
Material And Methods: Patients were evaluated in terms of their baseline biochemical characteristics, which included platelet count, serum creatinine and bilirubin levels, alanine transaminase (ALT) activity, international normalized ratio (INR) and Model for End-Stage Liver Disease (MELD) score.The efficacy endpoint was the achievement of a sustained virologic response at posttreatment week 12 (SVR12), defined as undetectable HCV RNA 12 weeks after the scheduled end of therapy.
A Comparison of Two DAAs Used in a Unique Model of Care to Treat Hepatitis C Infections in New Jersey.
Open Forum Infect Dis
December 2024
NJCRI, Newark, New Jersey, USA.
In this prospective observational study, we compare the efficacy of glecaprevir/pibrentasvir vs sofosbuvir/velpatasvir in treating hepatitis C within a unique model of care utilizing a combination of telehealth, an ambulatory van, case management, and a contracted pharmacy. Among 769 patients treated, 90.4% completed treatment, with 9.
View Article and Find Full Text PDFDirect Antivirals Can Achieve a Cure in All Patients With Chronic Hepatitis C due to Genotype 5: A French Multicentre Study.
Liver Int
November 2024
Department of Digestive and Hepatobiliary Medicine, CHU Clermont-Ferrand, Clermont-Ferrand, France.
Background: Hepatitis C virus genotype 5 (HCV-GT-5) is found mainly in South Africa. In our area in central France, the prevalence of HCV-GT-5 is 14%.
Methods And Results: Here we evaluated sustained virological response at week 12 post-treatment (SVR12) in 147 HCV-GT-5 patients from 14 French university hospitals (2014-2021) treated with direct-acting antivirals (DAA) in real-life.
Real-life data of hepatitis C treatment with direct acting antiviral therapy in persons injecting drugs or on opioid substitution therapy.
Infection
November 2024
Gemeinschaftspraxis Am Kaiserplatz, Bonn, Germany.
Article Synopsis
- HCV treatment has significantly improved with direct-acting antiviral therapy (DAA), allowing for shorter treatment durations and better tolerability in difficult-to-treat populations, such as people who inject drugs (PWID) and those on opioid substitution therapy (OST).
- A retrospective analysis of patients receiving DAA at a clinic in Bonn showed that all patients on glecaprevir/pibrentasvir completed their treatment, while 86% of those on sofosbuvir/velpatasvir did, resulting in a 74% sustained virological response (SVR) overall, despite some patients being lost to follow-up.
- The study highlights high adherence and SVR rates for HCV treatment in PWID, supporting efforts to
Prevalence of Drug Resistance Associated Substitutions in Persons With Chronic Hepatitis C Infection and Virological Failure Following Initial or Re-treatment With Pan-genotypic Direct-Acting Antivirals: A Systematic Review and Meta-analysis.
Clin Infect Dis
December 2024
Division of Geographic Medicine and Infectious Diseases, Tufts University School of Medicine, Boston, Massachusetts, USA.
Article Synopsis
- The introduction of direct-acting antivirals (DAAs) offers hope for eliminating hepatitis C virus (HCV) by 2030, but some patients (2%-12%) experience treatment failure, potentially due to existing drug resistance.
- A systematic review of 56 studies found a high prevalence of hepatitis C resistance-associated substitutions (RAS) among patients with virological failure after DAA treatment, ranging from 78% to 100% depending on the specific treatment regimen.
- The findings highlight the importance of monitoring DAA-associated resistance and understanding its implications for future treatment strategies.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!